Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR; UK Amantadine Study Group. Caronia S, et al. Among authors: irving wl. J Hepatol. 2001 Oct;35(4):512-6. doi: 10.1016/s0168-8278(01)00140-4. J Hepatol. 2001. PMID: 11682036 Clinical Trial.
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. Among authors: irving wl. J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5. J Hepatol. 2017. PMID: 28789880 Free article. No abstract available.
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. Among authors: irving wl. J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12. J Hepatol. 2018. PMID: 29339112 Free article. No abstract available.
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A, McLauchlan J, Smith D, Irving W, Cunningham M, Ansari A, Barnes E, Foster GR. Wing PAC, et al. Gastroenterology. 2019 Sep;157(3):692-704.e9. doi: 10.1053/j.gastro.2019.05.007. Epub 2019 May 10. Gastroenterology. 2019. PMID: 31078622 Free PMC article.
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. Martin NK, et al. J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7. J Viral Hepat. 2015. PMID: 25288193 Free PMC article.
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group.
Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK. Bradshaw D, et al. Among authors: irving wl. J Infect. 2019 Dec;79(6):503-512. doi: 10.1016/j.jinf.2019.10.007. Epub 2019 Oct 16. J Infect. 2019. PMID: 31629015 Free article. Review.
233 results